- Home
- KC vs VERA Comparison
KC vs VERA Comparison
Compare KC & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KC | VERA |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.0B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KC | VERA |
|---|---|---|
| Price | $9.90 | $33.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $18.00 | ★ $81.30 |
| AVG Volume (30 Days) | 1.3M | ★ 2.3M |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.93 | N/A |
| Revenue Next Year | $20.45 | $472.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.35 | $23.05 |
| 52 Week High | $18.52 | $56.05 |
Technical Indicators
Market Signals| Indicator | KC | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 48.37 |
| Support Level | $9.29 | $33.43 |
| Resistance Level | $11.06 | $36.89 |
| Average True Range (ATR) | 0.26 | 1.96 |
| MACD | -0.08 | -0.10 |
| Stochastic Oscillator | 31.34 | 39.83 |
Price Performance
Historical ComparisonAbout KC Kingsoft Cloud Holdings Limited
Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Security, Database, Data Analysis, Networking, and others. Its solutions are medical, government affairs, finance, media, education, gaming, Vehicle solutions, and others.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.